Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
UBS
Medtronic
Baxter
McKinsey
QuintilesIMS
Daiichi Sankyo
Teva
Covington

Generated: December 17, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RAMELTEON

« Back to Dashboard

Clinical Trials for Ramelteon

Trial ID Title Status Sponsor Phase Summary
NCT00237497 Safety and Efficacy of Ramelteon in Adults With Chronic Insomnia Completed Takeda Phase 3 The purpose of the study is to evaluate the safety and efficacy of Ramelteon, once daily (QD), compared to placebo with Zopiclone in adults with chronic insomnia
NCT00247390 Long-Term Efficacy and Safety of Ramelteon in Adults With Chronic Insomnia. Completed Takeda Phase 3 The purpose of this study to determine the long-term efficacy and safety of ramelteon, once daily (QD).
NCT00316992 Safety of Ramelteon in Subjects With Chronic Obstructive Pulmonary Disease Completed Takeda Phase 4 The purpose of this study is to determine if ramelteon has respiratory depressant effects in subjects with moderate to severe chronic obstructive pulmonary disease.
NCT00319215 Effects of Ramelteon on Driving Ability Completed Takeda Phase 1 The primary purpose of this study is to investigate the effects of bedtime administration of a single dose of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on next-morning on-road driving performance. In addition, the drugs' effects on balance are evaluated during the night, and the next morning residual effects on memory and psychomotor performance.
NCT00319215 Effects of Ramelteon on Driving Ability Completed Utrecht Institute for Pharmaceutical Sciences Phase 1 The primary purpose of this study is to investigate the effects of bedtime administration of a single dose of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on next-morning on-road driving performance. In addition, the drugs' effects on balance are evaluated during the night, and the next morning residual effects on memory and psychomotor performance.
NCT00325728 Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease Completed Takeda Phase 2 The purpose of this study is to determine the efficacy of ramelteon, once daily (QD), in subjects with mild to moderate Alzheimer's Disease and sleep disturbance
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Ramelteon

Condition Name

Condition Name for Ramelteon
Intervention Trials
Insomnia 16
Chronic Insomnia 13
Bipolar Disorder 5
Sleep Initiation and Maintenance Disorders 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ramelteon
Intervention Trials
Sleep Initiation and Maintenance Disorders 35
Disease 13
Parasomnias 6
Sleep Wake Disorders 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ramelteon

Trials by Country

Trials by Country for Ramelteon
Location Trials
United States 446
Mexico 11
Canada 7
Russian Federation 5
Colombia 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ramelteon
Location Trials
California 25
Ohio 22
Florida 22
New York 19
Texas 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ramelteon

Clinical Trial Phase

Clinical Trial Phase for Ramelteon
Clinical Trial Phase Trials
Phase 4 24
Phase 3 21
Phase 2 13
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ramelteon
Clinical Trial Phase Trials
Completed 40
Terminated 13
Not yet recruiting 7
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ramelteon

Sponsor Name

Sponsor Name for Ramelteon
Sponsor Trials
Takeda 44
Takeda Pharmaceuticals North America, Inc. 5
Massachusetts General Hospital 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ramelteon
Sponsor Trials
Industry 49
Other 40
NIH 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Cerilliant
Fuji
Colorcon
Dow
US Army
Harvard Business School
Accenture
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.